Nrx Pharmaceuticals Inc (NRXP) Stock Price, Quote & News

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-f...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 254 6134

Website: www.nrxpharma.com

Address:

1201 Orange Street, Suite 600, Wilmington, United States

MoneyGroupLLC Dec. 24 at 3:13 PM

Enter: $NRXP Calls Strike Price: $2 Expiry Date: JAN 16 2026 Buy in Price: $0.40 - $0.42 Sell Price: $0.87 Profit : +118% (Turn every $1 into $2.18) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

AIIAAIIA_88 Dec. 24 at 3:03 PM

$NRXP Are the NRXP warrants still trading? What is the current exercise price? Any time restriction? Asking for a friend. Thank you in advance.

1 · Reply

Outcomes Dec. 24 at 1:00 PM

$NRXP LIEBER PRIZE: Outstanding Achievement in Schizophrenia Research Daniel C. Javitt, M.D., Ph.D., Nathan Kline Institute for Psychiatric Research / Columbia University https://bbrfoundation.org/event/international-awards-dinner-2025

2 · Reply

Outcomes Dec. 24 at 12:51 PM

$NRXP “This is a major advancement in procedural sedation, since opioid-induced respiratory depression is associated with increased costs and lengths of stays for patients, Overall, findings confirm the relative absence of cardiopulmonary depression with ketamine/midazolam compared with fentanyl/midazolam sedation, affirming its critical safety advantage over traditional regimens,” https://radiologybusiness.com/topics/medical-imaging/interventional-radiology/ketamine-safe-sedation-alternative-interventional-radiology-suite

0 · Reply

Syndr78 Dec. 24 at 11:47 AM

$NRXP Are we actually going to be notified about the CNPV from the FDA by eoy??

1 · Reply

dontfeedthebashers Dec. 23 at 10:11 PM

$NRXP gonna be loading up on more warrants until CNPV award. we may see a spike on commons bc of the NDA news but the real gravy train will be once that voucher comes through.

3 · Reply

jonny80s Dec. 23 at 6:02 PM

$NRXP so what is the theory: everyone is waiting for Javitt to submit the 1 yr overdue NDA and make the 1 yr overdue clinic purchases so that he and everyone else can sell into the potential rally???

2 · Reply

Srinivas111 Dec. 23 at 2:46 PM

$TRIB $MYNZ $NRXP $VKTX

0 · Reply

jonny80s Dec. 23 at 2:25 PM

$NRXP here is a conspiracy theory for you: 1. The generic gets approved and so does the citizens petition. 2. Nephron screws up, cause Nephron… 3. Pfizer swoops in and buys Nephron/NRXP for Pennie’s on the dollar. If you ride the rollercoaster correctly you might get your money back.

0 · Reply

jonny80s Dec. 23 at 2:18 PM

$NRXP does anyone remember when I first spotted the $150-250 million in unexplained revenue in q4/q1 and started asking how that was gonna happen and certain Javitt supporters started/continued their he doesn’t know what he’s talking about campaign…..????? Yeah, you’re welcome.

0 · Reply

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Dec 3, 2025, 7:00 AM EST - 21 days ago

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

Dec 2, 2025, 11:23 AM EST - 22 days ago

NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript

Dec 2, 2025, 8:30 AM EST - 22 days ago

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

Dec 2, 2025, 7:30 AM EST - 22 days ago

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

Dec 1, 2025, 8:03 AM EST - 23 days ago

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference

Nov 17, 2025, 11:57 AM EST - 5 weeks ago

NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript

Nov 17, 2025, 8:03 AM EST - 5 weeks ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 8:31 AM EST - 6 weeks ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

Nov 10, 2025, 8:03 AM EST - 6 weeks ago

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

Oct 20, 2025, 8:03 AM EDT - 2 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

Oct 6, 2025, 8:03 AM EDT - 2 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

Sep 29, 2025, 8:03 AM EDT - 3 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

Sep 24, 2025, 8:03 AM EDT - 3 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

Sep 8, 2025, 8:17 AM EDT - 3 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

Sep 3, 2025, 8:03 AM EDT - 4 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

Sep 2, 2025, 1:19 PM EDT - 4 months ago

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

Sep 2, 2025, 8:41 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

Aug 27, 2025, 8:03 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

Aug 20, 2025, 12:23 PM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript

Aug 18, 2025, 8:10 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 6:06 PM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Aug 11, 2025, 4:05 PM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

Aug 11, 2025, 8:03 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

Aug 8, 2025, 8:03 AM EDT - 4 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)

Aug 4, 2025, 8:03 AM EDT - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products

Jul 29, 2025, 8:03 AM EDT - 5 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025

Jun 26, 2025, 8:03 AM EDT - 6 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

Jun 23, 2025, 8:03 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

Jun 16, 2025, 8:03 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

Jun 12, 2025, 8:03 AM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:03 AM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

May 16, 2025, 8:46 PM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript

May 15, 2025, 4:03 PM EDT - 7 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 10:15 AM EDT - 7 months ago

HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

May 13, 2025, 8:03 AM EDT - 8 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

May 12, 2025, 8:03 AM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025

May 6, 2025, 8:03 AM EDT - 8 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025

May 5, 2025, 8:03 AM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine

Apr 30, 2025, 8:46 AM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression

Apr 21, 2025, 8:01 AM EDT - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025

Apr 3, 2025, 8:03 AM EDT - 9 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

Mar 31, 2025, 8:02 AM EDT - 9 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics

Mar 24, 2025, 8:02 AM EDT - 9 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics

Mar 17, 2025, 10:50 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 8:02 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 8:01 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025

Feb 6, 2025, 8:03 AM EST - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025

Feb 3, 2025, 8:59 AM EST - 11 months ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor

Jan 28, 2025, 8:05 AM EST - 11 months ago

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition

MoneyGroupLLC Dec. 24 at 3:13 PM

0 · Reply

AIIAAIIA_88 Dec. 24 at 3:03 PM

$NRXP Are the NRXP warrants still trading? What is the current exercise price? Any time restriction? Asking for a friend. Thank you in advance.

1 · Reply

Outcomes Dec. 24 at 1:00 PM

2 · Reply

Outcomes Dec. 24 at 12:51 PM

0 · Reply

Syndr78 Dec. 24 at 11:47 AM

$NRXP Are we actually going to be notified about the CNPV from the FDA by eoy??

1 · Reply

dontfeedthebashers Dec. 23 at 10:11 PM

$NRXP gonna be loading up on more warrants until CNPV award. we may see a spike on commons bc of the NDA news but the real gravy train will be once that voucher comes through.

3 · Reply

jonny80s Dec. 23 at 6:02 PM

$NRXP so what is the theory: everyone is waiting for Javitt to submit the 1 yr overdue NDA and make the 1 yr overdue clinic purchases so that he and everyone else can sell into the potential rally???

2 · Reply

Srinivas111 Dec. 23 at 2:46 PM

$TRIB $MYNZ $NRXP $VKTX

0 · Reply

jonny80s Dec. 23 at 2:25 PM

0 · Reply

jonny80s Dec. 23 at 2:18 PM

0 · Reply

highbuyandlowsell Dec. 23 at 2:18 PM

$NRXP Those who blame, blame I'll think this is the floor and wait without selling it.

0 · Reply

jonny80s Dec. 23 at 12:57 PM

$NRXP this must be that quasi forward split Javitt teased after/during the reverse split a few years back.

0 · Reply

alwaysWinVlmr Dec. 23 at 9:47 AM

$NRXP the idiot bashers team activated again. Ansons is long now. Also you are welcome to sell. You advise others to sell, but you never sell yourself. Unless you were short all along? Then say so.

1 · Reply

the_franz Dec. 23 at 9:16 AM

$NRXP Prospectus: "As of December 11, 2025, there were 29,605,150 shares of Common Stock outstanding." Latest 10-Q: "As of November 13, 2025, the registrant had 28,097,627 shares of common stock [...] outstanding." Well, to say it in DonnieK style: THE RECENT DEBT-TO-EQUITY CONVERSION WITH ANSON HAPPENED LAST WEEK! And well, let's go back a year: "As of November 14, 2024, the registrant had 12,094,094 shares of Common Stock outstanding." The idiots here who always claimed that there would be no dilution are always so calm when shareholders get diluted again. 10% here, 10% there, it doesn't matter, right? Fuckers!

1 · Reply

FrugalMcLovin Dec. 23 at 7:10 AM

$NRXP Here’s one catalyst you can put on your calendar: NRx Pharmaceuticals has a GDUFA date of July 29, 2026, for its Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free intravenous ketamine, following FDA acceptance in December 2025. This date marks the goal for FDA review completion under the Generic Drug User Fee Amendments (GDUFA) program for this important generic product. Be aware, this GDUFA is for use as a generic drug for pain management, not for use to treat suicidal ideations. That would be a different application. There’s also more competition for pain management.

0 · Reply

TravisBking87 Dec. 23 at 3:52 AM

$NRXP

0 · Reply

jonny80s Dec. 23 at 2:12 AM

$NRXP so they have two different offerings in one week. $100M that they can sell to their friends that need to cover without causing a surge in market prices and another $150M to sell as they see fit. $250M/$1.5-2 give you 125-166m new shares or 500-600% dilution. Probably closer to 1000% dilution as the share price tumbles. 200-250mil shares here we come. Congrats Javitt on another year of screwing longterm shareholders over.

2 · Reply

mary46 Dec. 23 at 1:25 AM

$NRXP no big boyze buying? not good

0 · Reply

Sundreamer Dec. 22 at 11:52 PM

$NRXP December 22, 2025 A Form 424B3 has been filed with the United States Securities and Exchange Commission. https://ir.nrxpharma.com/node/10716/html

0 · Reply

MoneyGroupLLC Dec. 22 at 9:23 PM

Enter: $NRXP Calls Strike Price: $2 Expiry Date: JAN 16 2026 Buy in Price: $0.35 - $0.90 Sell Price: $0.64 Profit : +84% (Turn every $1 into $1.84) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Sookie1962 Dec. 22 at 9:19 PM

$NRXP good money making on the warrant today

0 · Reply

jonny80s Dec. 22 at 4:34 PM

$NRXP the Anson thing is weird. Am I right to assume they must have been holding roughly 400k short??? Which means they should have netted close to 2m shares from last week? Which would require them to file a 13d. Their last 13g/a shows them holding 1.6m shares as of 8/14. But their quarterly 13f has them at 2.03m shares as of 9/30. So shouldn’t there have been another 13g filed???? Plus the roughly 2.7m recently awarded for debt servicing….. Which would have to have a 13g and subsequent 13d filing, unless they used it to cover a short position or immediately sold it to someone else for a short position….

2 · Reply

Market Cap	70.76M
Revenue (ttm)	0.00
Net Income (ttm)	-25.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.39

Volume	195,300
Avg Vol	483,142
Day's Range	N/A - N/A
Shares Out	29.61M
Stochastic %K	86%
Beta	1.91
Analysts	Strong Sell
Price Target	$36.50